Royalty Pharma Eyes China’s Biotech Boom—Can Early Bets Deliver Solid Future Payouts? 

Royalty Pharma’s recent earnings for the second quarter of 2025 showcased significant progress, underscoring both strengths and areas of potential concern. Positively, Royalty Pharma achieved a 20% increase in Portfolio Receipts, reaching $727 million, surpassing prior guidance. The company also reported an 11% rise in Royalty Receipts to $672 million, attributed to the robust performance of its diversified portfolio. Another highlight was the strategic share repurchase program, with 8 million shares bought back, amounting to $1 billion in year-to-date repurchases. The company’s investment in value-creating royalty transactions, close to $600 million in the quarter, further demonstrates its commitment to growth and shareholder value.